TickerTalks
Browse all tickers →
TickerTalks›$OPK
OPOPK

OPKO Health, Inc.

$OPK·$1.2B·Medical - Diagnostics & Research·Healthcare
$1.57+5.4%YTD+24.6%1Y+9.8%
Price updated 23h ago·X counts updated 22h ago
OPOPK
$OPKOPKO Health, Inc.
$1.57+5.37%3 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $OPK on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

3X posts · last 7 days
Aug 29Sep 11

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $OPK — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Stuck sidewaysStalledAI verdict · as of 2026-09-11

The move has stalled — likely just drifts unless something new shows up.

Small-cap diagnostics-and-pharma name with mid-single-digit revenue growth but persistent losses — a low-multiple stock without a clear catalyst.

OPKO Health is a diversified diagnostics-and-pharmaceutical platform that keeps generating modest top-line growth without translating it into consistent operating profits.

  • Q2 revenue $163.6M grew 4.3% year-on-year and 32% sequentially — the sequential lift reflects lab-testing seasonality more than a durable trend — with operating margin at -4.3%.
  • Gross margin at 49% suggests the underlying product economics work, but corporate overhead relative to the revenue base keeps the P&L at a small loss; free-cash-flow yield of -11% shows cash burn continuing.
  • Debt-to-equity of 0.12 keeps the balance sheet clean, so the trade is more about the operating turn than about capital structure — this equity is priced as a real diagnostics-and-pharma company, just an unremarkable one.

Up 18% year-to-date but 6% over twelve months, the stock has range-traded around $1.50 for a long time. Any move requires a specific catalyst — a Phase 3 readout, an M&A deal, or a real operating turn — none of which is currently on the calendar.

What to watch: Q3 operating-margin trajectory versus the persistent -4% to -25% range, BioReference Labs test-volume growth as the diagnostics lever, and any partnership or licensing news that could reset the growth trajectory.

Read the AI verdict on $OPK

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Diagnostics and specialty pharma company with US lab services, growth hormone therapy, and international operations.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $OPK.

Medical - Diagnostics & Research · Healthcare

AI-driven diagnostic platforms (multi-cancer early detection, liquid biopsy) are the highest-growth segment; CRO demand from pharma R&D pipelines sustains contract research volume. Lab-equipment destocking has largely worked through, with instrument spend recovering.

What this means for $OPK

Partial — OPKO Health diagnostics/pharma; BioReference labs and specialty pharma, execution mixed.

Industry benchmark

16-name peer basket
+18.2%YTD
+42.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-17.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-8.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-25.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-10.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-5.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
42.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 27, 2026$-0.01$-0.08+87.5%
Q1 2026Apr 28, 2026$-0.07$-0.070.0%
Q4 2025Feb 26, 2026$-0.04$-0.07+42.9%
Q3 2025Oct 29, 2025$0.03$-0.02+250.0%
Next earningsWed, Nov 4·consensus EPS $-0.07

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$163.6M+4.3%48.9%-4.3%$-0.01$-46.5M
Q1 FY26$124.2M-17.2%21.6%-41.1%$-0.07$-21.1M
Q4 FY25$148.4M-19.2%30.3%-25.8%$-0.04$-28.6M
Q3 FY25$151.7M-12.6%20.0%-35.3%$0.03$-37.8M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$569.9M$567.3M – $573.7M-$0.22-$0.24 – -$0.195
FY27$589.0M$575.9M – $601.9M-$0.27-$0.29 – -$0.225
FY28$605.8M$602.8M – $608.8M-$0.24-$0.28 – -$0.212
FY29$651.4M$641.4M – $665.6M-$0.20-$0.21 – -$0.201
FY30$700.2M$689.4M – $715.4M-$0.19-$0.20 – -$0.191

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.79%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+12.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+20.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 323.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.505-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyMar 20John A PaganelliDirector10.0K sh$11K
+ 9 other (7 awards · 2 inkinds) in window

See when $OPK insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementAug 148-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
AI summary

OPKO Health, Inc. issued $125 million in additional senior secured notes on August 13, 2026 via an amendment to its July 2024 Note Purchase Agreement with HCR Injection SPV, LLC as agent. The notes mature July 17, 2044, bear interest at 3-month SOFR + 7.5% per annum (4.0% floor), with quarterly interest paid from EirGen Pharma's Pfizer profit-share royalties; they are secured by EirGen's royalty interest in mazdutide (Eli Lilly-licensed) and capped at $187.5M in Mazdutide repayments. This royalty-monetization financing ties OPKO's debt repayment directly to mazdutide's commercial traction in China, a material and long-dated obligation.

SC 13DActivist position (5%+)Aug 7SC 13D
AI summary

FROST PHILLIP MD ET AL 2 Check the appropriate box if a membe filed a new Schedule 13D disclosing a beneficial ownership position of 13.9% in OPK (OPK) as of 2026-08-07. This is a material ownership disclosure indicating significant shareholder interest that may signal activist or strategic intent. Investors should monitor for further 13D amendments, which could indicate evolving positions or demands on management.

SC 13D/AActivist amendmentJul 1SC 13D/A
AI summary

FROST PHILLIP MD ET AL filed an amended Schedule 13D for Common Stock, par value $0.01 per share (OPK) beneficially owning 255,429,406 shares. Reported for potential strategic or activist purposes. SC 13D is required when a beneficial owner crosses 5% with active intent. This amendment updates a prior position. Watch for follow-on disclosures about board engagement, deals, or governance proposals.

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
AI summary

OPKO Health, Inc (OPK) reported stockholder vote results (Item 5.07, filed 2026-06-18). Votes covered: director elections, equity plan. Proposals approved by shareholders. Annual votes cover routine governance; material proposals (equity plan expansions) warrant closer review. Check tallies for contested or close votes.

3New insider — initial holdingsMar 203
8-KOfficer or director changeMar 198-K — Item 5.02: Officer or director change
+ 10 other (4 10-Qs · 3 proxys · 2 earnings 8-Ks · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Monthsmarketbeat.com·2d agoAnalyzing HCA Healthcare (NYSE:HCA) & OPKO Health (NASDAQ:OPK)defenseworld.net·4d agoOPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conferenceglobenewswire.com·4d agoConnor Clark & Lunn Investment Management Ltd. Invests $618,000 in OPKO Health, Inc. $OPKdefenseworld.net·12d agoWhy Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?zacks.com·17d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$ILMN$A$TMO$DHR$NTRA$GH$PSNL
Voices on X · last 7 days

No standout posts about $OPK on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport